Haleon plc (LON:HLN)
London · Delayed Price · Currency is GBP · Price in GBX 359.50
-5.40 (-1.48%)
Jul 31, 2025, 5:12 PM BST
Elevation Oncology Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
Revenue | 11,019 | 11,233 | 11,302 | 10,858 | 9,545 | 9,892 | Upgrade |
Revenue Growth (YoY) | -2.12% | -0.61% | 4.09% | 13.76% | -3.51% | 16.65% | Upgrade |
Cost of Revenue | 4,015 | 4,130 | 4,340 | 4,129 | 3,561 | 3,791 | Upgrade |
Gross Profit | 7,004 | 7,103 | 6,962 | 6,729 | 5,984 | 6,101 | Upgrade |
Selling, General & Admin | 4,301 | 4,329 | 4,165 | 4,037 | 3,793 | 3,832 | Upgrade |
Research & Development | 306 | 297 | 297 | 303 | 248 | 296 | Upgrade |
Other Operating Expenses | -10 | -10 | 17 | -7 | - | - | Upgrade |
Operating Expenses | 4,597 | 4,616 | 4,479 | 4,333 | 4,041 | 4,128 | Upgrade |
Operating Income | 2,407 | 2,487 | 2,483 | 2,396 | 1,943 | 1,973 | Upgrade |
Interest Expense | -377 | -394 | -414 | -278 | -16 | -22 | Upgrade |
Interest & Investment Income | 81 | 65 | 25 | 56 | 13 | 14 | Upgrade |
Other Non Operating Income (Expenses) | 40 | 46 | -90 | 223 | -34 | -28 | Upgrade |
EBT Excluding Unusual Items | 2,151 | 2,204 | 2,004 | 2,397 | 1,906 | 1,937 | Upgrade |
Merger & Restructuring Charges | -103 | -213 | -171 | -49 | -45 | -502 | Upgrade |
Gain (Loss) on Sale of Assets | 124 | 121 | -10 | 24 | 31 | 212 | Upgrade |
Asset Writedown | -159 | -159 | -186 | -135 | -13 | -19 | Upgrade |
Other Unusual Items | -24 | -43 | -9 | -619 | -243 | -37 | Upgrade |
Pretax Income | 1,989 | 1,910 | 1,628 | 1,618 | 1,636 | 1,591 | Upgrade |
Income Tax Expense | 455 | 435 | 517 | 499 | 197 | 410 | Upgrade |
Earnings From Continuing Operations | 1,534 | 1,475 | 1,111 | 1,119 | 1,439 | 1,181 | Upgrade |
Minority Interest in Earnings | -12 | -33 | -62 | -59 | -49 | -36 | Upgrade |
Net Income | 1,522 | 1,442 | 1,049 | 1,060 | 1,390 | 1,145 | Upgrade |
Net Income to Common | 1,522 | 1,442 | 1,049 | 1,060 | 1,390 | 1,145 | Upgrade |
Net Income Growth | 39.89% | 37.46% | -1.04% | -23.74% | 21.40% | 74.81% | Upgrade |
Shares Outstanding (Basic) | 9,059 | 9,132 | 9,233 | 9,235 | 9,235 | 9,235 | Upgrade |
Shares Outstanding (Diluted) | 9,105 | 9,175 | 9,263 | 9,239 | 9,235 | 9,235 | Upgrade |
Shares Change (YoY) | -1.39% | -0.95% | 0.26% | 0.05% | - | - | Upgrade |
EPS (Basic) | 0.17 | 0.16 | 0.11 | 0.11 | 0.15 | 0.12 | Upgrade |
EPS (Diluted) | 0.17 | 0.16 | 0.11 | 0.11 | 0.15 | 0.12 | Upgrade |
EPS Growth | 41.64% | 38.94% | -1.55% | -23.75% | 21.40% | - | Upgrade |
Free Cash Flow | 2,226 | 2,051 | 1,866 | 1,759 | 1,128 | 1,185 | Upgrade |
Free Cash Flow Per Share | 0.24 | 0.22 | 0.20 | 0.19 | 0.12 | 0.13 | Upgrade |
Dividend Per Share | 0.068 | 0.066 | 0.060 | 0.024 | - | 2371.000 | Upgrade |
Dividend Growth | 9.68% | 10.00% | 150.00% | - | - | - | Upgrade |
Gross Margin | 63.56% | 63.23% | 61.60% | 61.97% | 62.69% | 61.68% | Upgrade |
Operating Margin | 21.84% | 22.14% | 21.97% | 22.07% | 20.36% | 19.95% | Upgrade |
Profit Margin | 13.81% | 12.84% | 9.28% | 9.76% | 14.56% | 11.58% | Upgrade |
Free Cash Flow Margin | 20.20% | 18.26% | 16.51% | 16.20% | 11.82% | 11.98% | Upgrade |
EBITDA | 2,626 | 2,683 | 2,674 | 2,683 | 2,211 | 2,190 | Upgrade |
EBITDA Margin | 23.83% | 23.89% | 23.66% | 24.71% | 23.16% | 22.14% | Upgrade |
D&A For EBITDA | 219 | 196 | 191 | 287 | 268 | 217 | Upgrade |
EBIT | 2,407 | 2,487 | 2,483 | 2,396 | 1,943 | 1,973 | Upgrade |
EBIT Margin | 21.84% | 22.14% | 21.97% | 22.07% | 20.36% | 19.95% | Upgrade |
Effective Tax Rate | 22.88% | 22.78% | 31.76% | 30.84% | 12.04% | 25.77% | Upgrade |
Advertising Expenses | - | 2,157 | 2,023 | 2,026 | 1,941 | 2,013 | Upgrade |
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.